Advances in PET imaging for meningioma patients

Norbert Galldiks; Nathalie L Albert; Michael Wollring; Jan-Michael Werner; Philipp Lohmann; Javier E Villanueva-Meyer; Gereon R Fink; Karl-Josef Langen; Joerg-Christian Tonn

doi:10.1093/noajnl/vdac113

Advances in PET imaging for meningioma patients

Neurooncol Adv. 2023 Jun 3;5(Suppl 1):i84-i93. doi: 10.1093/noajnl/vdac113. eCollection 2023 May.

Authors

Norbert Galldiks^{1

2

3}, Nathalie L Albert^{4

5}, Michael Wollring^{1

2}, Jan-Michael Werner^{1

2}, Philipp Lohmann⁶, Javier E Villanueva-Meyer⁷, Gereon R Fink^{1

2}, Karl-Josef Langen^{2

8}, Joerg-Christian Tonn^{4

9}

Affiliations

¹ Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
² Institute of Neuroscience and Medicine (INM-3, -4), Research Center Juelich, Juelich, Germany.
³ Center of Integrated Oncology (CIO), Universities of Aachen, Bonn, Cologne, and Düsseldorf, Germany.
⁴ German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
⁵ Department of Nuclear Medicine, University Hospital of Munich (LMU), Munich, Germany.
⁶ Department of Stereotactic and Functional Neurosurgery, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
⁷ Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California, USA.
⁸ Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.
⁹ Department of Neurosurgery, University Hospital of Munich (LMU), Munich, Germany.

Abstract

In patients with meningioma, diagnosis and treatment planning are predominantly based on anatomical imaging using MRI or CT. Constraints of these imaging modalities include precise meningioma delineation-especially at the skull base, in the case of trans-osseus growth, and in tumors with complex geometry-and the differentiation of post-therapeutic reactive changes from meningioma relapse. Advanced metabolic imaging using PET may help to characterize specific metabolic and cellular features providing additional information beyond the information derived from anatomical imaging alone. Accordingly, the use of PET in meningioma patients is steadily increasing. This review summarizes recent advances in PET imaging helpful for improving the clinical management of patients with meningioma.

Keywords: DOTATATE; FDG; FLT; SiTATE; amino acid PET; somatostatin receptor-expression.